We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Pathology Lab on Wheels Can Revolutionize Brain Surgery

By LabMedica International staff writers
Posted on 27 May 2022
Print article
Image: A pathology lab on wheels aims to revolutionize brain surgery (Photo courtesy of NYU Langone)
Image: A pathology lab on wheels aims to revolutionize brain surgery (Photo courtesy of NYU Langone)

Guesswork defines a central challenge of brain surgery. Cut too little and the residual tumor cells will reboot and kill the patient. Cut too much and critical brain functions could be irreversibly damaged. Studies show that in up to three-quarters of patients with brain cancer, portions of the tumor that could be safely removed are left behind, simply because the surgeon cannot see them. Without visual certainty, the risk of removing precious healthy tissue that could be involved in speech, memory, movement, or virtually any other important function of the brain is simply too high to cut beyond the known boundaries. Now, a radically new kind of imaging system helps brain surgeons cut with more confidence.

The new imaging system, now employed at the Brain and Spine Tumor Center at NYU Langone’s Perlmutter Cancer Center NYU Langone (New York, NY, USA), is called stimulated Raman histology, or SRH, a method that distinguishes tumor regions, rich in protein and DNA, from normal lipid-rich brain tissue, creating contrasted images akin to conventional histology slides. The technology is based on an old technique, Raman spectroscopy, used in chemistry since the 1920s, that involves shining a laser beam at a sample. The unique vibrational properties of different molecules change the optical properties of the laser, helping to create an image of the sample’s structure.

Pathologists can just as readily distinguish between cancerous and healthy tissue using the SRH images made in the operating room compared to the conventional ones created in the lab. The system works in concert with a powerful new diagnostic technique that leverages AI to distinguish among tumor types in less than two minutes, compared to the 20 to 30 minutes it typically takes human pathologists. The speed of diagnosis is a game changer, eliminating the time that a patient remains on the operating table while surgeons await lab results - a dangerous gap that increases the odds of infection or complications. Housed in a metal box about the size of a mini-fridge and mounted on wheels, the technology, which is now available to all NYU Langone Health patients with brain tumors, can be rolled into any operating room to provide a surgeon with near real-time analysis of a tissue sample.

“If we have a patient with a tumor of unknown etiology, for example, we might not know whether it’s glioblastoma or lymphoma - two tumors with very different treatments. Making the distinction in the operating room is extremely important,” said Daniel A. Orringer, MD. “Surgical decision-making is like operating brake and gas pedals. We are taking the guesswork out of the picture by allowing the surgeon to interrogate the tissue on a microscopic level and use imaging data to inform surgical strategy.”

Related Links:
NYU Langone 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more